Alteogen’s ‘Tergase Injection’ Clears Seoul Asan Medical Center’s Drug Committee

[Seungkwon kim, Edaily Reporter] Alteogen announced that Tergase Injection, South Korea’s first recombinant human hyaluronidase, has passed the drug committee at Seoul Asan Medical Center, the country’s largest tertiary hospital by bed capacity.

Launched in November, Tergase Injection is the first hyaluronidase in Korea produced through a recombinant method. Hyaluronidase is an enzyme that breaks down hyaluronic acid, improving the penetration of locally injected drugs and promoting the reabsorption of excess fluid or blood in tissues.

Tergase Injection (Photo=Alteogen)

Tergase Injection offers advantages over conventional animal-derived products, including higher purity, consistent enzymatic activity and a lower risk of side effects. The drug’s active ingredient, ALT-B4, is also a key component of Alteogen’s subcutaneous (SC) injection platform, Hybrozyme. The efficacy, safety and quality of Tergase Injection have been demonstrated through regulatory approval clinical trials, as well as trials conducted by global partners that have licensed the Hybrozyme technology.

The drug has shown strong safety results in clinical trials, notably without inducing anti-drug antibodies, ensuring consistent efficacy and safety even with repeated administration.

According to Alteogen Healthcare, which manages sales of Tergase Injection, the drug is currently prescribed at 16 major general hospitals, including Sanggye Paik Hospital, Daegu Catholic University Hospital and Gumi CHA Hospital. Seoul Medical Center, Jeonbuk National University Hospital and Hanyang University Guri Hospital have also approved its use.

Alteogen expects Tergase Injection will be available at about 30 hospitals nationwide soon, with the goal of securing prescription availability in all major university hospitals by midyear.

Go Jin-guk, vice president and head of sales and marketing at Alteogen Healthcare, said the approval by Seoul Asan Medical Center’s drug committee is a key milestone in making safer treatment options available to more patients.

Go said, “We are working with our promotional partner, PharmaResearch, to position Tergase Injection as the No. 1 hyaluronidase in Korea,” And, “We are also negotiating licensing agreements with overseas companies and aim to accelerate the global expansion of Tergase Injection,” he added.